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Abstract
The evolution of substitutions conferring drug resistance to HIV-1 is both episodic, occurring when patients are on
antiretroviral therapy, and strongly directional, with site-specific resistant residues increasing in frequency over time. While
methods exist to detect episodic diversifying selection and continuous directional selection, no evolutionary model
combining these two properties has been proposed. We present two models of episodic directional selection (MEDS and
EDEPS) which allow the a priori specification of lineages expected to have undergone directional selection. The models infer
the sites and target residues that were likely subject to directional selection, using either codon or protein sequences.
Compared to its null model of episodic diversifying selection, MEDS provides a superior fit to most sites known to be
involved in drug resistance, and neither one test for episodic diversifying selection nor another for constant directional
selection are able to detect as many true positives as MEDS and EDEPS while maintaining acceptable levels of false positives.
This suggests that episodic directional selection is a better description of the process driving the evolution of drug
resistance.
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Introduction
Among positively selected evolutionary changes, a distinction
can be made between diversifying selection, where any nucleotide
substitutions that change the amino acid are favored, and directional
selection, where only substitutions towards a small number of target
amino acids are selected for. Detection of genes or sites evolving
under positive selection [1–6] has been dominated by methods
which explicitly or implicitly assume diversifying positive selection.
This assumption allows evolution to be modeled as a continuous-
time Markov process without assuming that any particular residue
is the preferred target of substitutions at any sites. For most models
of diversifying selection, apart from a single rate governing amino
acid change, the process is no different from one site to the next.
By contrast, models have been proposed in which specific residues
do have special status at specific sites. In models of toggling
selection [7], substitutions away from a site-specific ‘‘wild type’’
amino acid are likely to be followed by reversions to that amino
acid. Models of directional selection [8,9] allow substitution rates
towards a site-specific ‘‘target’’ amino acid to be accelerated. By
making a distinction among all possible targets of a substitution,
such models allow the detection of positive selection favoring
mutations towards one amino acid, even at sites where the overall
rate of amino acid change is decreased by purifying selection. For
a review of codon models of selection, see [10].
A second distinction is that between selective pressure that is
constant over time, and selective pressure that changes over time,
possibly instantaneously – we shall refer to the latter as episodic
selection. Several authors have studied models that allow evolution-
ary rates to change over time, including models in which the
selective pressure is different on different branches [11–14] as well
as various models [15–17] in which the rate of evolution at any site
may change at any point in time. We are specifically interested in
the former type of model, under which rate changes occur
simultaneously at a particular set of sites - as would be expected
under an external change in selective pressure, i.e. episodic
selection. This type of selection is applicable to countless real world
scenarios that have been studied extensively: examples include the
evolution of lysozyme in response to diet changes [18], the
adaptation of HIV to different host populations [14], the evolution
of the rhodopsin pigment following changes in habitat [19], and
the adaptation of HIV-1 [20,21] and Influenza A Virus (IAV) [22]
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genes following zoonosis events. For a review on the evidence for
episodic selection in large numbers of protein sequences, see [23].
Here, we consider the evolution of drug resistance in HIV-1
following the treatment of a subset of the host population. We expect
that selective pressure will be both episodic, with drug-induced
adaptive amino acid changes occurring only in patients receiving
therapy, and directional, with site-specific target residues increasing
in frequency over time in the treated subset. HIV-1 experiences a
variety of other selective pressures, most prominently due to host
immune response (e.g. [14,24]), but because such response is nearly
unique in each host, we expect that the majority of concerted
selective changes in subjects on treatment will be drug-induced.
Previous approaches to detect positive selection driving
treatment resistance have had variable success. Crandall et al.
[25] showed that normalized ratios of non-synonymous to
synonymous substitution counts (dN=dS ) obtained by the counting
method of Nei and Gojobori [1] failed to show consistent
evidence of selection, despite obvious resistance associated
substitutions occurring in parallel in many patients. Chen et al.
[26] used a contingency-table counting method to characterize
positive selection towards specific amino acids in a sample of
approximately 40000 sequences. However, their approach
ignored the phylogenetic relationships between samples which
can cause selection to be conflated with founder effects [22,27].
Lemey et al. [28] used the branch-site model of Yang and Nielsen
[12] – a model of episodic diversifying selection – to analyze the
evolution of drug resistance over a transmission chain. A number
of sites were inferred to be under positive selection, of which some
were associated with drug resistance. Seoighe et al. [8] modeled
the evolution of reverse transcriptase between pre- and post-
treatment samples from 300 patients. They successfully detected
some of the major drug resistance mutations with few false
positives.
In this paper we aim to demonstrate that explicitly modeling the
directional and episodic character of the evolution of drug
resistance increases the power and accuracy to detect drug
resistance sites. We introduce a codon-based Model of Episodic
Directional Selection (MEDS) and a model of protein evolution
called Episodic Directional Evolution of Protein Sequences
(EDEPS), and show that both models outperform models that
lack either the episodic or directional components.
Models
MEDS
Our codon model of episodic directional selection assumes that
branches on the phylogenetic tree can be partitioned into fore-
ground (F) and background (B) subsets a priori. Evolution along
background branches is described by a standard codon model (QB,
see below). In the model for foreground branches (QF ), directional
selection is incorporated via an elevated rate of substitutions towards
a target amino acid.
MEDS extends two previously proposed models of coding
sequence evolution: 1) the episodic component of MEDS is
structurally identical to the Internal Fixed Effects Likelihood
(IFEL) model proposed in [14], although IFEL is used to detect
diversifying selection along internal branches only, and, 2) the
directional component is introduced in a manner similar to that in
the model of directional selection proposed by Seoighe et al. [8].
We used MG94|REV [29] as our baseline codon model: it
combines a general time-reversible (GTR) model of nucleotide
substitution with separate synonymous (a) and non-synonymous
(b) rates. To facilitate reading, table 1 summarizes the properties of
each model.
Following Seoighe et al. [8] we add a directional selection
parameter vT to modulate the rate of substitutions to the target
residue T in the model assigned to foreground branches. If
AA(x) represents the amino-acid encoded by codon x, then the
instantaneous rates of change between codons i and j (i=j) are
given by:
Author Summary
When exposed to treatment, HIV-1 and other rapidly
evolving viruses have the capacity to acquire drug
resistance mutations (DRAMs), which limit the efficacy of
antivirals. There are a number of experimentally well
characterized HIV-1 DRAMs, but many mutations whose
roles are not fully understood have also been reported. In
this manuscript we construct evolutionary models that
identify the locations and targets of mutations conferring
resistance to antiretrovirals from viral sequences sampled
from treated and untreated individuals. While the evolu-
tion of drug resistance is a classic example of natural
selection, existing analyses fail to detect the majority of
DRAMs. We show that, in order to identify resistance
mutations from sequence data, it is necessary to recognize
that in this case natural selection is both episodic (it only
operates when the virus is exposed to the drugs) and
directional (only mutations to a particular amino-acid
confer resistance while allowing the virus to continue
replicating). The new class of models that allow for the
episodic and directional nature of adaptive evolution
performs very well at recovering known DRAMs, can be
useful at identifying unknown resistance-associated muta-
tions, and is generally applicable to a variety of biological
scenarios where similar selective forces are at play.
Table 1. Summary of models described in this manuscript.
Model Data Baseline model Site variation Lineage variation Selection test Citation
MEDS Codon MG94|REVa Fixed effects Episodic Directional This paper
FEEDS Codon MG94|REV Fixed effects Episodic Diversifying [14]b
DEPS Protein HIV-Betweenc Random effects Constant Directional [9]
EDEPS Protein HIV-Between Random effects Episodic Directional This paper
a[29].
bFEEDS has the same structure as a model called IFEL in that paper, but the use here is novel.
c[37].
doi:10.1371/journal.pcbi.1002507.t001
Episodic Directional Selection
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QFi,j~
0,when i and j differ at more than one position, otherwise :
h(i,j)|a|pij when AA(i)~AA(j)
h(i,j)|bF|pij when AA(i)=T&AA(i)=T&AA(i)=AA(j)
h(i,j)|bF|vT|pij when AA(i)=T&AA(j)~T
h(i,j)|bF|1=vT|pij when AA(i)~T&AA(i)=T
8>>><
>>>:
ð1Þ
for the foreground and
QBi,j~
0,when i and j differ at more than one position, otherwise :
h(i,j)|a|pij when AA(i)~AA(j)
h(i,j)|bB|pij when AA(i)=AA(j)
8><
>:
ð2Þ
for the background branches. We assume that a does not change
significantly between foreground and background branches.
Indeed, available evidence (e.g. [30–32]) suggests that synonymous
rate variation among sites is due to biological processes which
change slowly, e.g. RNA secondary structure, transcriptional or
translational efficiency, relative to the nearly instant change in the
selective environment due to the presence of ARV. In principle,
the model can readily handle such variation. bF and bB can be
inferred independently. h(i,j) is the GTR-based rate of the
underlying nucleotide substitution from codon i to j, shared
between QF and QB. Equilibrium frequency parameters pij are
derived with the corrected F3|4 estimator [33]. While the same
pij values are used for background and foreground models, when
vT=1 the equilibrium frequencies of QF will depart from those
dictated by pij , although we do not need to calculate these new
equilibrium frequencies explicitly. This feature is essential because
directional evolution changes the character frequencies at a site.
We also experimented with a version of the model where the factor
1
vT
in the last line of Equation 1 was omitted – this had essentially
no impact on the results. To ensure that Q defines a valid Markov
process generator, along the diagonal of Qwe set:
Qi,i~{
X
j,j=i
Qi,j : ð3Þ
Model fitting proceeds in two stages: (a) estimating the
parameters shared across sites, and (b) site-wise analysis [6,34].
The branch lengths and QF and QB, without the directional
component (i.e. vT~1), are first optimized over the entire
alignment to obtain gene-wide parameter estimates in the presence
of potentially ubiquitous purifying or diversifying selection. The
nucleotide rate parameters (h(i,j)) and relative branch lengths are
then fixed for subsequent analyses. From then, the analysis
proceeds site by site. We define the null model by setting vT~1, a
special case of the alternative directional model (vT is free to vary),
and equivalent to IFEL [14]. The null model has 3 free parameters
per site: a (synonymous substitution rate), bF (non-synonymous
substitution rate along foreground lineages) and bB (non-synon-
ymous substitution rate along backfround lineages). The alterna-
tive model has a single additional parameter, vT , biasing
substitutions towards T . To test for selection towards amino acid
T at a specific site, we obtain maximum likelihood scores for the
null and alternative models and perform a likelihood-ratio test
(LRT) with one degree of freedom based on the asymptotic x2
distribution of the likelihood-ratio statistic.
The above test treats nucleotide substitution rates and branch
length parameters at a single site as known, even though these are
estimated across sites under a simpler model. It is possible that this
could affect inference if these estimates were substantially biased.
Our simulations suggest that the test performs well in spite of this
computational shortcut, and using different models to infer these
parameters does not substantially affect the test results on the
empirical data we analyze here. Additionally, the x2 asymptotic
approximation implicit in MEDS relies on the intuition that when
the number of sequences increases, the number of branches in the
tree will increase, so that substitutions on those branches will
constitute different (although dependent) realizations of the
process. We note that the asymptotic approximation for our test
requires not only many branches but also many foreground
branches. While theoretical results justifying our use of the x2
approximation are currently lacking, our simulations (see below)
suggest that the use of the x2 appears to lead to a conservative test
for the conditions we have examined.
Scanning a site for selection towards any possible amino acid (T )
involves testing 20 hypotheses, and we employ Bonferroni
correction [35] to control the site-wise Type I error rate. For
computational efficiency, we skip invariant sites and restrict
potential values of T to those observed at a given site. Because
these reductions are informed by the data, we still employ the 20-
test Bonferroni correction at each site.
FEEDS
To assess the importance of the directional component of
MEDS, we adapt IFEL to test for episodic diversifying selection
along foreground branches and use it as a benchmark for
MEDS. As the branches of interest are mostly terminal, the
name, IFEL, is no longer appropriate, and we rename the
model FEEDS, for ‘Fixed Effects Episodic Diversifying Selec-
tion’. The alternative model for FEEDS is identical to the null
model for MEDS, allowing a, bF and bB to vary for each site.
To test for non-neutral selection along foreground branches, we
set up a null model with bF~a, and use an LRT (one degree of
freedom) to determine whether the alternative model fits better
than the null model. If bFwa results in a significant likelihood
improvement, we have evidence for diversifying selection along
foreground branches. This test for episodic diversifying selection
has three features that distinguish it from the popular branch-
site model of Yang and Nielsen [12] and Zhang, Nielsen and
Yang [36]: 1) it uses a sitewise likelihood-ratio test [5], otherwise
known as a fixed effects likelihood [6] approach, 2) it allows site-
to-site synonymous rate variation, which has been shown to be
ubiquitous and can cause spurious detection of diversifying
selection if ignored [29] and 3) it allows diversifying selection on
the background branches in both the null and alternative
models. MEDS shares these properties, allowing us to attribute
any performance differences specifically to the directional
component of MEDS.
DEPS
Throughout the analyses we also compare our results against
DEPS (full results in tables S1 to S3), a method for detecting non-
episodic directional selection proposed by Kosakovsky Pond et al.
[9]. DEPS identifies sites with increased substitution rates towards
specific amino acids, but it differs from MEDS in three ways: 1)
DEPS models directional selection at the amino acid level rather
than the codon level, 2) DEPS uses a Random Effects Likelihood
(REL) framework to bias selection towards target amino acids
across all sites, relying on an empirical Bayes analysis to identify
sites of interest and 3) in DEPS, directional selection affects all
branches of the phylogeny.
Episodic Directional Selection
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Episodic DEPS
It is a straightforward exercise to modify DEPS to incorporate
the episodic nature of MEDS – namely, we restrict accelerated
substitutions towards a target residue T (and retard substitutions
away from it) to foreground branches, while background branches
always evolve according to the baseline protein substitution model
specific to HIV-1 [37]. The entire testing framework of DEPS, as
described in Kosakovsky Pond et al. [9], applies without change. It
is well known that amino acid substitution rates depend on the
residues involved (e.g. see [38]), and specifying a baseline model
which includes unequal substitution rates provides a qualitative
advance over MEDS. Conversely, because DEPS works with
protein sequences, the natural proxy of approximately neutral
evolution (the rate of synonymous substitutions) is not available.
All models and their accompanying LRTs are implemented in a
HyPhy Batch Language script [39], and all code and test datasets
are available on the MEDS section of the HyPhy wiki (www.
hyphy.org) and included in the latest HyPhy distribution (version
2.0020101225 or later).
Datasets
We analyzed three HIV-1 datasets obtained from the South
African mirror of the Stanford HIV Drug Resistance Database
(HIVdb) [40,41]. Synthetic datasets were generated by simulation
to investigate the power and false positive rate of MEDS. The
primary goal of this paper is to show that MEDS and EDEPS
perform well on medium-sized datasets constructed under a
variety of conditions. Every empirical dataset includes sequences
sampled from both treated and untreated patients, but we varied
the inclusion criteria from one dataset to the next. An ideal dataset
for detecting drug resistance would include pre- and post-
treatment samples from the same patients (as in our reverse
transcriptase dataset), but often such data are not available, e.g.
when sequences are obtained from patients experiencing regimen
failure. To evaluate the performance of MEDS and EDEPS when
pre- and post-treatment sequence pairs were not available (our
protease and integrate datasets), we selected pre-treatment
sequences using heuristic measures of proximity to the post-
treatment samples, as one would be forced to do under such
circumstances. Exactly which factors are responsible for perfor-
mance variation is left as a topic for future research. The objective
of each analysis was to detect sites (and corresponding amino
acids) that are involved in drug resistance. For validation, we used
the curated list of drug resistance associated mutations (DRAMs)
which is available from the Stanford HIVdb (http://hivdb.
stanford.edu). This list is produced every year and approved by
the International AIDS Society (http://www.iasusa.org/
resistance_mutations/). These mutations have been rigorously
validated with genotype-phenotype and genotype-clinical data and
are known to confer varying levels of resistance to one or more
antiretroviral agents – they can therefore be used as a ground truth
for evaluating the performance of our methods.
We screened each sequence for evidence of recombination
(known to have a biasing effect on selection detection, e.g. [42])
using SCUEAL [43] and excluded any sequences showingw90%
support for either inter- or intra-subtype recombination, and using
the Rega HIV-1 Subtyping tool Version 2.0 [44], excluding any
sequences with clear inter-subtype recombination.
Reverse transcriptase. The first dataset comprises pairs of
reverse transcriptase (RT) isolates obtained before and after the
initiation of highly active anti-retroviral therapy (HAART) from
241 patients (482 sequences). The data were obtained from the
Stanford HIVdb using a query that retrieved paired samples from
the same patient, filtered on the earlier sample being Reverse
Transcriptase Inhibitor (RTI) naive, and the later sample taken
during therapy with at least one Non-Nucleoside RTI (NNRTI)
and at least one Nucleoside RTI (NRTI). The topology of the
phylogeny was estimated using PhyML [45] (settings for all
datasets: REV model with tree search by Nearest Neighbor
Interchange and Subtree Pruning and Regrafting), and all
terminal branches leading to post-treatment sequences were
selected as foreground (see Figure S1). As an artifact of older
sequencing assays [14], a large number of sequences were missing
data at the beginning and end of RT, hence we analyzed the
region from codon 40 to 250. Six sequences were excluded from
our analyses because they displayed evidence of recombination.
Protease. A dataset consisting of 49 protease isolates (from 37
patients), sampled post-Protease Inhibitor (PI) treatment was
retrieved from HIVdb (query: Number of PIs = 3, Subtype = C).
Additionally, the entire collection of treatment naive protease
isolates was obtained, and all full length sequences were searched
for two sequences nearest (under the Hamming distance) to each
of the 49 post-treatment sequences. The final dataset was
constructed by combining the post-treatment and closely related
naive sequences: a total of 122 sequences, as some naive sequences
were closely related to more than one post-PI sequence. Since
protease is only 297 nucleotides long, we were concerned that
convergent evolution due to drug resistance might inflate the
apparent relatedness between some of the treatment resistant
sequences [46], hence we excluded the major resistance sites
before reconstructing the phylogeny, using PhyML. As there are
many instances where a number of post-treatment sequences were
sampled from a single patient, we adopted a recursive branch
labeling strategy for the internal branches. All terminal branches
leading to post-PI and PI-naive isolates were labeled as foreground
and background respectively, and internal branches were labeled
Figure 1. The maximum-likelihood phylogeny for the protease
dataset. Foreground branches are marked in red. All terminal
foreground branches lead to sequences obtained from patients who
had been receiving antiretroviral therapy. See text for details of how we
determined which internal branches were assigned to foreground.
MEDS and EDEPS allow the presence of a directional component along
the foreground branches where antiretroviral therapy exerts selective
pressure.
doi:10.1371/journal.pcbi.1002507.g001
Episodic Directional Selection
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as foreground if both child branches were foreground, and
background otherwise (See figure 1). This labeling ensures that
drug resistance selection occurs only on foreground branches.
Because there may be portions of foreground branches not under
drug selection, the effect of potential mislabeling is to dilute the
signal along foreground branches and reduce the power of the test.
No sequences showed evidence of recombination.
Integrase. The post-treatment sequences for the final empir-
ical dataset were 83 integrase isolates sampled from 40 patients
after Integrase Inhibitor (II, Raltegravir) therapy. 1237 II-naive
isolates were obtained from the Stanford HIVdb, and the final
Raltegravir dataset was made up of 315 sequences: the 83 post-II
isolates, plus the union of the 25 II-naive isolates nearest to each of
the 83 post-II isolates under the HKY85 distance [47]. The
topology of the phylogeny was again estimated using PhyML, and
the foreground region was labeled in the same fashion as the
protease dataset (see Figure S2). 20 sequences were excluded for
showing evidence of recombination.
Power simulations. We investigated the power of MEDS
by simulating alignments over a balanced 64-taxon phylogeny
(see Figure S3 for an example). All parameters were varied (see
Text S1 for complete details). Of particular interest, we simulated
under 4, 8, 16 or 32 foreground branches and, selecting a
random target amino acid T for each site, the directional
selection parameter vT took values of 2, 5, 10, 100 and 1000.
These vT values are in a reasonable range: in our three empirical
datasets, the 25%, 50% and 75% percentiles of the maximum-
likelihood estimates of vT values for detected substitutions are
32:2, 629:9 and 5544:3. 400 sites were simulated for each vT
value, for each number of foreground branches, yielding 8000
simulated sites. To assist in understanding the effects of vT and
the size of the foreground subset, we also recorded the number of
Table 2. Sites under episodic directional and episodic diversifying selection in reverse transcriptase.
Site Target MEDS p-valuea vT (Lower 99% CI)
b FEEDS p-valuec EDEPS Bayes Factord Resistance
41 L 0:00259 1937 (280.06) -e - NRTIf
62 V - - - 313 NRTI
64 K 0:00244 11:99 (5.58) 0:0067 -
77 L - - - 211 NRTI
98 S 0:00488 w1000 (w1000) - -
100 I v0:0001 w1000 (524.49) - w105 NNRTIg
102 ?h - - 0.0025 -
103 N v0:0001 629:9 (466.73) v0:0001 w105 NNRTI
104 Y 0:00244 w1000 (90.81) - -
115 F - - - 3110 NRTI
116 Y 0:00319 w1000 (179.80) - - NRTI
151 M v0:0001 w1000 (186.13) - w105 NRTI
151 Q 0:00023 13:96 (7.04) - -
162 S - - - 1772
165 L v0:0001 w1000 (w1000) - 2245
174 R - - - 105
181 I v0:0001 w1000 (118.72) - w105 NNRTI
184 V v0:0001 25:82 (16.68) - w105 NRTI
188 L v0:0001 377:93 (32.42) 0:0002 w105 NNRTI
188 Y v0:0001 17:61 (11.15) - -
190 S v0:0001 75:85 (26.09) - w105 NNRTI
200 ? - - v0:0001 -
215 F 0:00282 160:65 (10.36) - 2727 NRTI
215 T 0:00035 15:19 (6.69) - -
228 R 0:00029 72:2 (14.09) - 1401 NRTI accessory
230 L 0:00297 w1000 (44.6) - w105 NNRTI
245 ? - - 0.0006 -
286 A 0:00085 w1000 (w1000) - -
aMEDS versus FEEDS LRT, testing for directional selection.
bthe lower bound of the approximate 99% confidence interval calculated from profile likelihood.
cbFwa LRT, testing for diversifying selection.
dEmpirical Bayes analysis, testing for directional selection on protein data.
e‘-’: not significant.
fNucleoside reverse-transcriptase inhibitor.
gNon-nucleoside reverse-transcriptase inhibitor.
h?: detected only by FEEDS which does not identify a target AA.
doi:10.1371/journal.pcbi.1002507.t002
Episodic Directional Selection
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substitutions towards the target amino acid that occurred along
foreground branches.
In real evolving systems, the modeling assumption of selection
towards a single target amino acid could be violated. We
investigated how such deviations would impact the power of the
model by simulating directional selection towards two target
amino acids, with substitutions towards one target accelerated on 8
foreground branches, and substitutions towards another acceler-
ated on a different 8 foreground branches. The parameters were
varied in the same manner as the single-target power simulation,
and 1600 sites were simulated for each vT value, again yielding
8000 sites in total.
False positive simulations. We used exactly the same
simulation configuration and parameters to asses the rates of false
positives under the null model (vT~1). We simulated 400 sites for
each of 4, 8, 16 or 32 foreground branches.
In evolving proteins, each site could have its own site-specific
selective constraints governing amino acid distributions. MEDS
assumes that background equilibrium frequencies are the same for
all sites, and a potential concern is that deviations from this
Table 3. Sites under episodic directional and episodic diversifying selection in protease.
Site Target MEDS p-valuea vT (Lower 99% CI)
b FEEDS p-valuec EDEPS Bayes Factord Resistance
10 ?e -f - 0.0005 - PIg accessory
12 T v0:0001 28:88 (8.58) - -
13 V 0:0059 490:2 (138) - 145 PI accessory
35 D 0:0035 8:56 (1.99) - -
54 ? - - 0.0026 - PI
60 E v0:0001 w1000 (w1000) - - PI accessory
61 E v0:0001 w1000 (w1000) - -
71 V - - 0.0011 257 PI accessory
74 S 0:0007 19:93 (4.08) 0.0013 - PI accessory
82 A - - v0:0001 w105 PI
84 V 0:00798 890:3 (248.19) - w105 PI
90 M v0:0001 w1000 (986.17) v0:0001 w105 PI
93 L 0:0078 w1000 (6.36) - - PI accessory
aMEDS versus FEEDS LRT, testing for directional selection.
b99% lower confidence interval calculated from the likelihood profile.
cbFwa LRT, testing for diversifying selection.
dEmpirical Bayes analysis, testing for directional selection on protein data.
e?: detected only by FEEDS which does not identify a target AA.
f‘-’: not significant.
gProtease inhibitor.
doi:10.1371/journal.pcbi.1002507.t003
Table 4. Sites under episodic directional and episodic diversifying selection in integrase.
Site Target MEDS p-valuea vT (Lower 99% CI)
b FEEDS p-valuec EDEPS Bayes Factord Resistance
72 I 0:0095 w1000 (533.76) -e - INIf accessory
97 A 0:0028 337 (105.52) v0:0001 w105 INI accessory
140 S v0:0001 w1000 (w1000) 0:0003 w105 INI
143 R 0:0015 23:5 (3.83) v0:0001 w105 INI
148 H v0:0001 35:5 (14.53) v0:0001 w105 INI
155 H v0:0001 w1000 (w1000) 0:0006 w105 INI
163 R - - - 1143 INI accessory
221 Q - - - 107
227 ?g - - 0.0064 -
230 ? - - 0.0048 - INI accessory
aMEDS versus FEEDS LRT, testing for directional selection.
b99% lower confidence interval calculated from the likelihood profile.
cbFwa LRT, testing for diversifying selection.
dEmpirical Bayes analysis, testing for directional selection on protein data.
e‘-’: not significant.
fIntegrase inhibitor.
g?: detected only by FEEDS which does not identify a target AA.
doi:10.1371/journal.pcbi.1002507.t004
Episodic Directional Selection
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modeling assumption could lead to excessive false positives. To
investigate this, we simulated data under a version of the null
model where each site’s amino acid equilibrium frequencies were
sampled from a symmetric Dirichlet distribution with density
f (qp; a)* P
20
p~1
qa{1p ð4Þ
The concentration parameter a took values 0.005, 0.05, 0.5 and 5,
varying the equilibrium frequency distributions from extremely
peaked to relatively flat. Each sampled amino-acid frequency qp
was evenly distributed among all codons encoding p and a version
of QB with the Goldman-Yang parameterization of equilibrium
frequencies [4] was employed to simulate codon sequence data.
Results
Reverse transcriptase
MEDS detected twenty substitutions at seventeen sites under
significant directional selection at pƒ0:01, after correcting for
multiple tests (see tables 2 and S4). Of these, five are known NRTI
drug resistance associated mutations (DRAMs) (41L, 116Y, 151M,
184V and 215F) and six are known NNRTI DRAMs (100I, 103N,
181I, 188L, 190S and 230L). Additionally, 228R is listed as an
accessory NRTI mutation. The eight detected substitutions that
have not been experimentally or clinically associated with drug
resistance are 64K, 98S, 104Y, 151Q, 165L, 188Y, 215T and
286A. Interestingly, at three of these sites (151, 188 and 215)
selection was detected both towards the wildtype and towards
resistant residues. EDEPS agreed with MEDS on eleven sites,
detected additional DRAMs 62V, 77L and 115F, missed two
MEDS-reported DRAMs (41L and 116Y), and found episodic
selection at 162S and 174R which are not known to confer drug
resistance.
Remarkably, FEEDS detected only six sites under diversifying
selection (table S5), two of which are known resistance mutations,
strongly supporting the inclusion of a directional component in the
model. A continuous directional selection model (DEPS) detected
46 sites under directional selection with Bayes factors w100 (see
table S1), only ten of which are on the HIVdb list. This indicates
that focusing our attention on branches where the evolutionary
environment shifts is advantageous for finding evidence of
adaptive response to such shifts.
Protease
MEDS detected nine substitutions under directional selection at
pƒ0:01 (tables 3 and S6). Of these, two are major DRAMs (90M
and 84V). Three are accessory polymorphic mutations (13V, 60E
and 93L) under selective pressure from the drugs. 74S is a non-
polymorphic accessory mutation. EDEPS agreed with MEDS on
three (13V, 84V and 90M), detected one more major mutation,
82A, and an accessory mutation at 71V. Interestingly, 60E and
61E found by MEDS involve substitutions (D?E and Q?E)
which, in HIV, are much more frequent than the mean
substitution rate [37]. Because MEDS sets the background rate
of non-synonymous substitutions to the same value for all pairs of
residues, it could use vT to compensate for the overall underes-
timation of rates that are much greater than the mean rate.
FEEDS identified six sites involved in diversifying selection
(table S7), with all six listed on HIVdb. In addition to two sites
already detected by MEDS (74 and 90), sites 10 and 71 are listed
as accessory mutations, while 54 and 82 are major resistance
mutations. DEPS appeared to be much more conservative on this
dataset, detecting four sites under directional selection, two of
which are listed on HIVdb (see table S2).
Integrase
MEDS detected six substitutions under significant directional
selection at the 1% level (see tables 4 and S8). Four (140S, 143R,
148H and 155H) appear on the HIVdb list of mutations associated
with aw5{10 fold decrease in Raltegravir susceptibility. Two are
listed as mutations selected by Raltegravir (72I and 97A). EDEPS
confirmed five DRAMs (97A, 140S, 143R, 148H and 155H),
together with a 163R accessory substitution and a 221Q mutation
which is not a known DRAM.
FEEDS found seven sites under diversifying selection (table S9),
six of which are known resistance mutations. 230 is the only
correctly identified resistance site in the integrase dataset that is
detected as being under diversifying selection by FEEDS, but not
directional selection by MEDS. 230 R and N are listed as selected
by Raltegravir. DEPS detected 39 substitutions under directional
selection (see table S3), nine of which appear on the HIVdb list.
Comparing methods
Comparing the fit of FEEDS and MEDS on known resistance
sites in all three datasets, LRTs reject a null model of FEEDS in
favor of MEDS on 24 sites, with FEEDS being favored on five
(four from protease and one from integrase). Note that FEEDS
might still be useful for detecting these sites, but the LRT
demonstrates that MEDS is a better model of the process. This
suggests that episodic directional selection is, in most cases, a
better characterization of the evolution of drug resistance. Overall,
FEEDS detects fourteen true positives, while MEDS and EDEPS
detect 24 each (although not the same 24). Where FEEDS appears
to have a reasonably low rate of false positives but misses a large
number of true positives, DEPS detects a large number of true
positives but with a very high false positive rate. This is expected as
DEPS will detect substitutions under selection along background
branches that are not related to drug resistance.
Power simulations
The power of MEDS, like that of other codon methods, strongly
depends on the information content of the sequences, specifically
on the number of times that substitutions toward the target occur
along the foreground lineages. For example, even when vT is
1000, no substitutions towards T occur on half the sites simulated
on the phylogeny with sixteen foreground branches. The primary
reason for this is that vT affects only the instantaneous substitution
rate from a codon to its direct neighbors; if none of the direct
Table 5. Single target power simulations: power as a function
of vT .
# FG
branches vT
2 5 10 100 1000
4 0 (8)a 0 (16) 0 (37) 0.31 (110) 0.79 (155)
8 0 (11) 0 (18) 0.04 (62) 0.51 (129) 0.73 (170)
16 0 (31) 0.018 (54) 0.036 (83) 0.59 (177) 0.71 (201)
32 0.02 (62) 0.03 (71) 0.16 (116) 0.68 (223) 0.80 (282)
aNumbers in brackets are the number of times at least one substitution towards
the target occurred along foreground branches: i.e. the denominator for the
proportion of detections.
doi:10.1371/journal.pcbi.1002507.t005
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neighbors of T are visited along a foreground branch, a change in
vT will not affect the process.
Hence, we tabulate MEDS results only for sites with at least one
substitution towards the target on any foreground branch. Table 5
shows that the power is positively correlated with vT . MEDS
appears to be quite powerful, even when the number of
foreground branches is small, achieving, for example, 51% power
with vT~100 with only eight foreground branches. Table 6
displays the power of MEDS conditioned on the number of
substitutions towards the target on foreground branches. With
only one substitution there is almost no power, but moderate
power (&30%) occurs with two substitutions towards T , and with
five or more substitutions towards T , the power is almost 100%.
For data simulated with two target residues, each on eight
foreground branches, the occurrence of at least one substitution
towards both targets is infrequent. From 4800 sites simulated with vT
values of 2, 5 and 10, this occurs only 58 times, and is never detected.
From 1600 sites simulated withvT~100 for both targets, substitutions
to both targets occur 174 times. MEDS detects substitutions to at least
one target in 47% of such sites, but only detects substitutions to both
targets in 5% of such sites. With vT~1000, we see 306 of 1600 sites
with substitutions to both targets, and MEDS detects substitutions to at
least one target in 86% of these sites, and to both targets in 31%.
Table 7 shows how the power increases with the number of
substitutions towards both targets on the foreground branches.
Since there too many possible combinations and too few
observations, we display power in a cumulative manner (i.e. §N
substitutions towards both targets).
False positive simulations
MEDS behaves conservatively. With data simulated under the
null model, far fewer sites are identified as under episodic
directional selection than would be expected from the nominal
p-value thresholds. Across all four foreground configurations, only
one false positive detection (pv0:01, with Bonferroni correction)
occurs on the 32 foreground branch phylogeny, and none on the
others. With pv0:05, with 4, 8, 16 and 32 branches, we have false
positive rates of 0, 0.0025, 0.0075 and 0.01; with pv0:1, we have
0.005, 0.005, 0.0125 and 0.02, respectively. This is most likely due
to FEL methods being generally conservative [6] as well as the
conservative nature of Bonferroni correction. The effect of the
correction is compounded because increasing the frequency of one
amino acid reduces the frequency of the others, and thus the
twenty tests are not independent. Table 8 shows the false positive
rate for alignments simulated under site specific equilibrium
frequencies. MEDS is still conservative under this scenario, and
the false positive rates do not appear to be influenced by the
concentration parameter.
Discussion
We have proposed a codon (MEDS) and a protein (EDEPS)
model of episodic directional selection, and demonstrated their
performance on three HIV-1 datasets, where drug-induced
directional episodic selection is expected to operate. We have also
proposed a model of episodic diversifying selection (FEEDS), to
rigorously evaluate the importance of modeling the directional
component of natural selection. As expected, on all datasets, our
episodic directional tests strongly outperform a test for continuous
directional selection (DEPS) for detecting drug resistance sites. The
assumptions of DEPS are inappropriate for the analysis of episodic
selection, where selection is limited to specific regions of the
phylogeny, because DEPS assumes uniform selection over the
whole phylogeny. This serves as a caution against using
suboptimal models, rather than a criticism of DEPS.
We tested MEDS with extensive simulations. MEDS is a
conservative test, even when strong constraints on the amino acid
state space are introduced in the form of site-specific equilibrium
frequencies. Under the alternative model, good power is achieved
even when relatively few substitutions towards target amino acids
take place along foreground branches. When we deviate from the
alternative model and elevate the substitution rate towards several
target residues, the power to detect both targets is lower than it
would be assuming independence. This reduction in power is
Table 7. Dual target power simulations: power as a function of number of substitutions to two target AAs.
Substitutions to both targetsa: §1 §2 §3 §4 §5 §6 §7 ~8
MEDS detects at least one target: 0.64 0.81 0.89 0.92 0.95 0.98 1 1
MEDS detects both targets: 0.19 0.36 0.48 0.52 0.63 0.76 0.78 0.81
Total sites: 538 288 214 179 132 99 69 32
aSubstitutions along foreground branches. Each target has 8 foreground branches along which changes towards it were accelerated.
doi:10.1371/journal.pcbi.1002507.t007
Table 6. Single target power simulations: power as a function
of number of substitutions to target AA along foreground
branches, pooling over vT .
# FG
branches # substitutions to target AA
0 1 2 3 4 §5
4 0 (1674)a 0 (119) 0.2 (58) 0.77 (48) 0.99 (111) N/A
8 0 (1610) 0 (146) 0.23 (53) 0.69 (26) 1 (21) 0.99 (144)
16 0 (1454) 0 (200) 0.34 (92) 0.49 (39) 0.79 (34) 0.97 (181)
32 0 (1246) 0.03 (234) 0.4 (107) 0.41 (70) 0.70 (46) 0.97 (297)
aNumbers in brackets are the number of times that many substitutions towards
the target occurred along foreground branches: i.e. the denominator for the
proportion of detections.
doi:10.1371/journal.pcbi.1002507.t006
Table 8. False positives with site specific equilibrium
frequencies as a function of the concentration parameter a
and the nominal p-value of the test.
a parameter: 0.005 0.05 0.5 5
p~0:01 0.005 0.0025 0.0025 0.0075
p~0:05 0.02 0.0175 0.02 0.015
p~0:1 0.0325 0.0325 0.035 0.0375
doi:10.1371/journal.pcbi.1002507.t008
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expected: as the number of targets along foreground branches
increases, the directional nature of the process is lost.
Hughes [48] argues that diversifying selection is only appropri-
ate for modeling pathogen-host co-evolution, and that the
constantly shifting environment is required for the standard
diversifying selection model to be appropriate. Our results
highlight that models of diversifying selection also serve as
reasonable approximations in instances where selective constraints
allow escape to many different residues, such as codon 54 in
protease, which has V, T, A, L and M as major drug resistant
residues. However, at most sites conferring drug resistance,
directional models better approximate reality – positive selection
acts only on one or a few specific mutations, while the rest are
suppressed by purifying selection. The simulations presented in
Table 7 illustrate how much power MEDS can be expected to
have in cases such as site 54 in protease. This example also
suggests a future extension of MEDS, where instead of considering
one target residue at a time, substitution rates could be elevated
towards classes of target residues.
Another interesting property of directional models is exempli-
fied by a substitution in the protease dataset. 93L is a polymorphic
mutation selected for by protease inhibitors. Despite L already
being the most common residue in subtype C, the model detects
selective pressure towards it – the proportion of L residues is
indeed lower in nave sequences. At the population level this
appears as purifying selection: the most common amino acid
increases in frequency. This is nevertheless detected by our test.
Far from being problematic, such information could be useful for
directing treatment, if it turns out that patients with I at position
93 are more susceptible to PI therapy. Such observations should,
of course, be directly verified with clinical data.
There are clear differences in organism-wide amino acid
exchangeabilities in HIV-1 [37], yet the null model of MEDS
(and the vast majority of other codon-models) posit that the non-
synonymous substitution rate does not depend on the residues. We
evaluated the effect of this assumption by comparing MEDS with
an episodic version of DEPS – a test that specifically incorporates a
heterogeneous exchangeability matrix in the evolutionary model.
With a few exceptions, MEDS and EDEPS return overlapping sets
of directionally evolving residues and identify the same targets.
There are several sites in protease and integrase, where MEDS
may be misclassifying non-uniform exchangeabilities as directional
selection, hence another extension of MEDS would be to
incorporate multiple non-synonymous substitution rates [38].
MEDS and EDEPS were designed with HIV-1 drug resistance
in mind, but should be applicable wherever episodic directional
selection occurs along multiple lineages. To use the models, two
specific conditions must be met: 1) Lineages expected to be under
directional selection must be known a priori, at least approximately.
This is necessary to partition the phylogeny into foreground and
background regions. 2) A rich collection of background sequences
are needed. With HIV-1, this translates to requiring treatment
naive sequences. Variety in these sequences is also important. If all
the background sequences were so closely related that the
foreground and background regions were separated by a single
branch, if would be difficult to separate directional selection from
founder effects, which would result in a loss of power. If the
background sequences are spread about the phylogeny, however,
founder effects are rendered unlikely and the test for directional
selection should be well powered.
With HIV-1 drug resistance datasets, the foreground labeling
strategy might prove important. On the RT dataset, branch-
labeling was straightforward, as we had access to pre-treatment
sequences for each patient. This is not the case for most real-world
datasets, and other approximate labeling schemes, as well as the
robustness of the results to these differences, should be investigated.
Another consideration is the rooting of the tree. With directional
models, the expected amino acid frequencies change across the
phylogeny, and the position of the root becomes important [9].
With MEDS and EDEPS, the directional component only affects
foreground branches. Consequently, the tree can be rooted on any
background branch and the likelihood will be unaffected [49].
Amidst growing concerns about an epidemic of circulating drug
resistant HIV-1, the WHO and SATuRN are recommending a
scale-up of drug resistance surveillance [41,50]. This is to ensure the
long-term success of the world’s largest antiretroviral treatment
programs, located in Africa. We see improved models of the
sequence evolution playing a role in characterizing local differences
in treatment resistance patterns, perhaps driven by different
treatment regimens, adherence and transmission dynamics, and
possibly identifying new resistance mutations.
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